more stories from investigations
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.. .
.
the total amount paid out in life claims was £129.4m, with £13.46m paid in terminal illness claims.
Take up to 10% off with code